Zapify Research
Get the free guideFree guide
Peptide guide

GLOW

A pre-blended stack of GHK-Cu, BPC-157, and TB-500, sold for skin quality and whole-body soft-tissue recovery in one vial.

GLOW isn't a single peptide. It's three of them blended in one vial: GHK-Cu, BPC-157, and TB-500, usually in a 5:1:1 ratio that makes it GHK-Cu-dominant. The pitch is one subcutaneous shot that covers both skin quality and soft-tissue recovery. None of the three is FDA-approved, the human evidence is thin, and blending them means you give up dose control over each one. People still run it for the convenience, so the practical questions are what each part actually contributes, how to reconstitute and draw the combined vial, and how not to get scammed buying it.

By the Zapify Research team
Reviewed against 12 clinical & research sources · Updated June 2026 · Educational use only
Type
3-peptide blendGHK-Cu / BPC-157 / TB-500
Route
SubcutaneousInjected once daily
Typical dose
~2.3 mg blend/day≈10 units once daily
Cycle
4–6 wks on2–4 wks off
Storage
Mixed: 2–4 wksSealed: months
Status
Not FDA-approved

What is GLOW?

A fixed 5:1:1 blend of GHK-Cu, BPC-157, and TB-500 in one vial — convenient, but you lose the ability to dose any one peptide on its own.

GLOW is a blend, not a compound. A single vial holds three separate peptides: GHK-Cu, BPC-157, and TB-500. The usual mix is a 5:1:1 ratio, often sold as 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 in a 70 mg vial. That ratio is GHK-Cu-heavy, which is where the name comes from: GHK-Cu is the copper peptide most tied to skin quality, collagen, and that 'glow' people are after.

Each piece does a different job. GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that drops in your plasma by roughly 60% between age 20 and 60, and it's the one linked to collagen, elastin, and skin remodeling. BPC-157 is a 15-amino-acid peptide studied mostly for tendon, ligament, and gut repair. TB-500 is a thymosin beta-4 fragment studied for cell migration and soft-tissue recovery. The idea behind stacking them is that they hit different stages of healing at once: BPC-157 around new blood-vessel growth, TB-500 around moving repair cells to where they're needed, GHK-Cu around laying down collagen and rebuilding skin.

The trade-off built into a blend is dose control. With a fixed ratio in one vial, you can't dial GHK-Cu up for a skin goal without also raising the other two, and you can't run BPC-157 at its own optimal schedule. Some people buy three separate vials and run them independently for exactly that reason. GLOW trades that precision for the convenience of one daily subcutaneous shot.

No component of GLOW is FDA-approved, and the blend itself certainly isn't. The injected forms have essentially no completed human efficacy trials, and GHK-Cu's human data comes mostly from topical studies rather than the injected peptide. Injectable GHK-Cu was placed on the FDA's restricted Category 2 bulk-substances list in 2023, and an April 2026 FDA announcement signaled it would be removed from that list by July 2026 — easing compounding access, not granting approval. Treat GLOW as an experimental research stack, not a proven medicine.

What is it studied for?

No study has ever tested the blend itself; only the three peptides separately, and that research is uneven and mostly animal data.

No study has tested the GLOW blend as a blend. What exists is the separate research behind each peptide, and that research is uneven. BPC-157 has dozens of animal studies and only a single small human one. The TB-500 fragment has animal and cell-culture work but no completed human efficacy trials. GHK-Cu has the most human data of the three, though most of it comes from topical studies rather than the injected peptide in this vial.

Human evidence, by injected component
Thin — human data mostly topicalGHK-Cu (injected)
1 small studyBPC-157
NoneTB-500 fragment

The research clusters around what each peptide is supposed to bring to the stack:

GHK-Cu — skin & collagenThe skin-quality half of GLOW. Human trials report increased collagen density and improved dermal thickness; a 2023 study reported roughly a 28% average rise in collagen density at three months.
BPC-157 — tissue repairTendons, ligaments, joints, and gut lining in animal work. Brings the new-blood-vessel and connective-tissue angle to the blend.
TB-500 — cell migrationHelps repair cells move toward a wound in animal and lab studies. The whole-body recovery and flexibility piece of the stack.

The mechanisms are each plausible on their own, and they do overlap in ways that make the stacking logic coherent: angiogenesis, cell migration, and collagen deposition are genuinely different stages of repair. What's unproven is whether injecting all three together in a fixed ratio reproduces any of it in a living human. That's the biggest open question in the whole stack.

Why people use it

People run it to chase skin quality and soft-tissue recovery in a single daily shot, though no human trial shows the injected blend delivers either.

Most people who run GLOW are chasing two things at once and want them in a single injection. These are the reasons they reach for it, not evidence that it delivers:

  • Wanting both skin quality and recovery without juggling three separate vials and three separate schedules.
  • A skin-first goal — firmness, tone, the look of aging skin — leaning on GHK-Cu as the dominant component.
  • Stubborn soft-tissue wear from hard training, where BPC-157 and TB-500 are already the go-to stack and GHK-Cu rides along.
  • Convenience and cost, since a pre-blend is one purchase and one daily shot instead of three.
No human trial has shown the injected GLOW blend will do any of this. What's there is three peptides with coherent, complementary mechanisms, a deep track record for GHK-Cu on skin, and consistent animal signals for BPC-157 and TB-500. It's worth being curious about. It isn't enough to rely on, and the blend's fixed ratio means you can't tune any one component to a specific goal. It also won't replace the basics with real evidence behind them: sleep, rehab, sun protection, and loading tissue properly.

How to reconstitute GLOW

Mix a 70 mg vial with 3 mL bacteriostatic water for 23.3 mg/mL, so 10 units draws about 2.33 mg of blend; swirl, never shake.

Your vial arrives as a small puck of dry powder holding all three peptides together. Before you can inject it, you mix it into a liquid you'll draw into an insulin syringe. That step is called reconstitution, and it's the same process used for BPC-157 and TB-500 on their own.

Step 1Start with powderWipe the rubber stopper with an alcohol swab.
Step 2Add bac. waterRun it slowly down the inside wall — never shake.
Step 3Draw your doseThe calculator gives the exact units to draw to.
  • Wipe the rubber stopper with an alcohol swab first, every time.
  • Use bacteriostatic water, not plain sterile water and not saline. The trace of benzyl alcohol in it holds back bacteria, which matters because you'll be drawing from the same vial for weeks.
  • Add the water slowly, running it down the inside glass wall. Don't blast it straight onto the powder.
  • Don't shake it. Swirl gently and let it dissolve on its own. Shaking foams the solution and can damage the peptides.

A common setup for a 70 mg blend vial is 3 mL of bacteriostatic water, which gives 23.3 mg/mL of total blend. On a U-100 insulin syringe, 10 units drawn for a subcutaneous shot is then about 2.33 mg of blend, delivering roughly 1.67 mg GHK-Cu, 0.33 mg BPC-157, and 0.33 mg TB-500. The water doesn't change how much peptide is in the vial; it only sets the concentration, which decides how many units you draw. Because the ratio is locked, you're always drawing all three in the same proportion, so the only lever you have is total volume.

Calculate your exact GLOW reconstitution →

Dose & units

No FDA dose exists; reports cite about 10 units (~2.3 mg blend) subcutaneously once daily, cycled roughly 4–6 weeks on and 2–4 off.

There is no FDA-approved dose for GLOW or for any of its three components. Everything below is a range that sellers and write-ups report, not a medical standard. Because GLOW is a fixed-ratio blend, every dose moves all three peptides together, so you can't follow a single-peptide protocol for any one of them. Decide what goes into your body with a licensed provider, not with this page.

Typical range

For the standard 5:1:1 blend, reported daily dosing lands around 10 units on a U-100 syringe, roughly 2.3 mg of total blend, taken subcutaneously once a day. That works out to about 1.67 mg GHK-Cu, 0.33 mg BPC-157, and 0.33 mg TB-500 per shot. Run as separate vials, the same compounds report differently: GHK-Cu around 1–2 mg/day, BPC-157 around 250–500 mcg/day, and TB-500 a few milligrams a week split into two shots. The blend keeps GHK-Cu in its usual range while landing the other two on the lower side.

Titration

Most write-ups start near the low end and hold there for the first week or two before adjusting, mostly to watch for a reaction to GHK-Cu, which is the component people feel first. Because copper rides along with every dose, going higher isn't a free move; more blend means more copper, not just more recovery peptide.

Cycling

Reported cycles run about 4–6 weeks on followed by 2–4 weeks off, with longer 8–12 week runs cited too. The copper in GHK-Cu is the reason people cycle rather than run it indefinitely: a defined on/off schedule limits how much copper accumulates over time.

On4–6 weeks
Off2–4 weeks

For the exact mark to draw to on your insulin syringe, don't eyeball it. The calculator turns your vial size, water, and dose into the precise number of units for your subcutaneous draw, and for a three-peptide blend it also shows how much of each component a given draw delivers.

Get your exact units →

Storage

Sealed powder lasts months, but a reconstituted vial keeps only about 2–4 weeks refrigerated — set by its shortest-lived component, TB-500.

Sealed & drySealed dry powder stays stable for months and tolerates shipping heat; many sellers freeze blends for long-term storage.
ReconstitutedRefrigerate at 2–8 °C and use within about 2–4 weeks; don't freeze, keep out of light, discard if cloudy or discolored.
You'll see longer windows quoted for peptide vials. Those figures are beyond-use dates for a sealed, unmixed vial that a compounding pharmacy has stability-tested, and they stop applying the moment you add water. A mixed vial runs on the shorter clock instead, because that's how long the preservative in bacteriostatic water reliably keeps the solution clean once you're drawing from it. With a blend, the shortest-lived component sets the limit, so treat it like the TB-500 window rather than the longer one.

That limit is about sterility, not strength — the peptides themselves often stay good well beyond it. Reconstitute with plain sterile water instead of bacteriostatic and you drop to a day or two, since there's no preservative holding bacteria back.

Don't freeze a reconstituted vial, keep it out of direct light, write the mix date on the label, and throw it out if the solution ever turns cloudy or discolored, whatever the date says. GHK-Cu gives a reconstituted blend a faint blue tint from the copper, which is normal; cloudiness or a color shift away from that is not.

Side effects & safety

Effects are reportedly mild but stack all three peptides plus a copper load; avoid with copper-overload conditions, and BPC-157 is WADA-banned.

The reported side effects are generally mild, but a blend carries the side-effect profile of all three peptides at once, plus the copper load from GHK-Cu. That picture comes from animal studies, GHK-Cu skin research, and scattered user reports, not large human safety trials of the injected blend, so hold it loosely.

  • Most common: mild, short-lived redness, irritation, or stinging at the injection site, often attributed to the GHK-Cu component.
  • Less often: brief fatigue or light-headedness in the first days of a cycle, mild nausea, or temporary flushing.
  • Tied to the copper: with high or prolonged GHK-Cu dosing, the theoretical concern is copper accumulation, which matters most for anyone with a copper-handling condition.
Talk to a doctor before you start if you have a history of cancer. All three peptides touch new-blood-vessel growth or cell migration, the same processes that could in theory feed tissue you don't want growing. That's unproven, but worth taking seriously. GHK-Cu adds specific cautions: avoid it with Wilson's disease or other copper-overload conditions, and be cautious with retinal vascular disorders given the angiogenic overlap. The usual cautions apply too if you're pregnant, breastfeeding, or managing a serious health condition.

If you compete, the blend is a problem on its own. BPC-157 was added to the WADA Prohibited List in 2022, and thymosin beta-4 and its fragments (TB-500) have been prohibited since 2011, banned both in and out of competition under the S0 non-approved-substances category. GHK-Cu itself isn't on the WADA Prohibited List, but it doesn't matter here: injecting GLOW means injecting two banned peptides regardless. A positive test is a doping violation.

And the biggest risk here isn't really any one molecule. It's whether the vial actually contains GHK-Cu, BPC-157, and TB-500, in the ratio and at the strength on the label. A blend gives a seller three things to get wrong instead of one, and you can't see any of it in the powder. That comes down to where you buy it.

How to vet a source

Demand a third-party COA that names all three peptides, their purity, and the ratio, with a lot number matching your vial — not a screenshot.

This is an unregulated market, and a real share of independently tested vials come back underdosed, impure, or not even the compound on the label. A blend raises the stakes: a real certificate of analysis has to confirm all three peptides, their purity, and the actual ratio, not just one of them. With GHK-Cu, BPC-157, and TB-500 in the same vial, a seller can short the cheap-to-fake components and you'd never know from the powder. The one document that separates a real seller from a gamble is a certificate of analysis: a third-party lab's report on what's actually in the vial.

A real COA shows
  • An identity test (usually mass spectrometry) confirming the peptide is what the label says.
  • A purity figure from HPLC, typically 98% or higher.
  • A lot or batch number that matches the number printed on your vial.
  • A named, independent accredited lab and a recent test date.
Walk away if
  • There’s no COA, or it’s a generic image with no lot number.
  • The “certificate” comes from the seller instead of a third-party lab.
  • The lot number doesn’t match your vial, or there isn’t one at all.
  • It’s a flat image you can’t trace back to the lab that issued it.

That's the standard worth holding any seller to, ours included. For a blend, push it further: ask for a COA that names each of the three peptides and their purity, match the lot number to your vial, and don't accept a screenshot in place of a traceable report.

See the Zapify compound catalog →

Common questions about GLOW

Is GLOW one peptide or several?
Several. GLOW is a pre-blended stack of three peptides in one vial: GHK-Cu, BPC-157, and TB-500, usually in a 5:1:1 ratio (commonly 50 mg / 10 mg / 10 mg). It's sold as a single product, but you're injecting all three together every time, in a fixed proportion you can't adjust.
Is GLOW approved or proven to work in people?
No. None of the three components is FDA-approved, and the injected blend has no human efficacy trials of its own. BPC-157 has only a single small human study, and the TB-500 fragment is backed by animal work alone. GHK-Cu has the most human data of the three, though most of it comes from topical studies rather than the injected peptide in this vial.
Why is GLOW associated with skin specifically?
Because GHK-Cu dominates the blend. The 5:1:1 ratio means most of what you inject is GHK-Cu, the copper peptide tied to collagen, elastin, and skin remodeling. BPC-157 and TB-500 are present in much smaller amounts and contribute the soft-tissue recovery side. The 'glow' in the name is the GHK-Cu skin angle.
Should I use GLOW or buy the three peptides separately?
It depends on what you want. The blend is convenient and cheaper, one shot a day, but the fixed ratio means you can't raise GHK-Cu for a skin goal without also raising the other two, or run BPC-157 on its own optimal schedule. People who want dose control over each compound buy three separate vials and run them independently. Neither path is FDA-approved, and a licensed provider should be in the loop either way.
Does GLOW matter for drug testing?
Yes, and badly. BPC-157 was added to the WADA Prohibited List in 2022, and thymosin beta-4 and its fragments (TB-500) have been prohibited since 2011, both banned in and out of competition. GHK-Cu itself isn't banned, but that's irrelevant here, since injecting GLOW means injecting two prohibited peptides. For any tested athlete, a positive is a doping violation.
Why does reconstituted GLOW look slightly blue?
That's the copper in GHK-Cu. A faint blue tint in a reconstituted blend is normal and comes from the copper ion bound to the peptide. What's not normal is cloudiness, particles, or a color shift away from that clear, faintly blue look, which means you should throw the vial out regardless of the date.

References

  1. Peptide Dosing Protocols — GLOW Stack: BPC-157 + TB-500 + GHK-Cu Dosing, Benefits, and Guidance (2026)
  2. PeptideDeck — Glow Stack: GHK-Cu + BPC-157 + TB-500 Dosing, Synergy & Results
  3. Pickart, Vasquez-Soltero & Margolina — GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (BioMed Research International, 2015)
  4. Copper peptide GHK-Cu — Wikipedia (discovery 1973 by Pickart, plasma decline with age, glycyl-L-histidyl-L-lysine sequence)
  5. PeRx Peptides — Is GHK-Cu FDA Approved? (injectable not approved; topical OTC cosmetic; compoundable status)
  6. FDA Law Blog (Hyman, Phelps & McNamara) — FDA's Pep(tide) Rally: 503A bulk substances, Category 2 placement of BPC-157 and TB-500, and the 2026 PCAC review
  7. PeptideDosages.com — GHK-Cu Dosage Chart, 50 mg Vial Protocol
  8. Vasireddi et al. — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025; 35 preclinical + 1 clinical study)
  9. Rahaman et al. — Simultaneous quantification of TB-500 and its metabolites with in-vitro wound-healing screening (Journal of Chromatography B, 2024)
  10. USADA — BPC-157: Experimental Peptide Creates Risk for Athletes (prohibited under S0)
  11. WADA — Prohibited List (thymosin β4 and fragments prohibited in and out of competition under S0)
  12. Pickart, Vasquez-Soltero & Margolina — GHK-Cu may Prevent Oxidative Stress in Skin (Cosmetics, MDPI, 2015)
This page is for research and educational purposes only. It is not medical advice or a recommendation to use any compound. The dose ranges shown are reported by clinics and research literature, not validated medical standards, and GLOW is not FDA-approved. Talk to a licensed medical provider about anything you put in your body.